1
|
Rosenfeld EH, Vogel A, Russell RT, Maizlin I, Klinkner DB, Polites S, Gaines B, Leeper C, Anthony S, Waddell M, St Peter S, Juang D, Thakkar R, Drews J, Behrens B, Jafri M, Burd RS, Beaudin M, Carmant L, Falcone RA, Moody S, Naik-Mathuria BJ. Comparison of diagnostic imaging modalities for the evaluation of pancreatic duct injury in children: a multi-institutional analysis from the Pancreatic Trauma Study Group. Pediatr Surg Int 2018; 34:961-966. [PMID: 30074080 DOI: 10.1007/s00383-018-4309-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/23/2018] [Indexed: 12/26/2022]
Abstract
PURPOSE Determining the integrity of the pancreatic duct is important in high-grade pancreatic trauma to guide decision making for operative vs non-operative management. Computed tomography (CT) is generally an inadequate study for this purpose, and magnetic resonance cholangiopancreatography (MRCP) is sometimes obtained to gain additional information regarding the duct. The purpose of this multi-institutional study was to directly compare the results from CT and MRCP for evaluating pancreatic duct disruption in children with these rare injuries. METHODS Retrospective study of data obtained from eleven pediatric trauma centers from 2010 to 2015. Children up to age 18 with suspected blunt pancreatic duct injury who had both CT and MRCP within 1 week of injury were included. Imaging findings of both studies were directly compared and analyzed using descriptive statistics, Chi square, Wilcoxon rank-sum, and McNemar's tests. RESULTS Data were collected for 21 patients (mean age 7.8 years). The duct was visualized more often on MRCP than CT (48 vs 5%, p < 0.05). Duct disruption was confirmed more often on MRCP than CT (24 vs 0%), suspected based on secondary findings equally (38 vs 38%), and more often indeterminate on CT (62 vs 38%). Overall, MRCP was not superior to CT for determining duct integrity (62 vs 38%, p = 0.28). CONCLUSIONS In children with blunt pancreatic injury, MRCP is more useful than CT for identifying the pancreatic duct but may not be superior for confirmation of duct integrity. Endoscopic retrograde cholangiogram (ERCP) may be necessary to confirm duct disruption when considering pancreatic resection. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- Eric H Rosenfeld
- Texas Children's Hospital and the Michael E DeBakey Department of Surgery, 6701 Fannin Street # 1210, Houston, TX, 77030, USA.
| | - Adam Vogel
- Texas Children's Hospital and the Michael E DeBakey Department of Surgery, 6701 Fannin Street # 1210, Houston, TX, 77030, USA
| | - Robert T Russell
- University of Alabama at Birmingham, Children's of Alabama, Birmingham, AL, USA
| | - Ilan Maizlin
- University of Alabama at Birmingham, Children's of Alabama, Birmingham, AL, USA
| | | | | | | | | | | | | | | | - David Juang
- Children's Mercy Hospital, Kansas City, MO, USA
| | | | - Joseph Drews
- Nationwide Children's Hospital, Columbus, OH, USA
| | - Brandon Behrens
- Randall Children's Hospital at Legacy Emanuel Medical Center, Portland, OR, USA
| | - Mubeen Jafri
- Randall Children's Hospital at Legacy Emanuel Medical Center, Portland, OR, USA
| | | | - Marianne Beaudin
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - Laurence Carmant
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | | | | | - Bindi J Naik-Mathuria
- Texas Children's Hospital and the Michael E DeBakey Department of Surgery, 6701 Fannin Street # 1210, Houston, TX, 77030, USA
| |
Collapse
|
2
|
Best C, Fukunishi T, Drews J, Khosravi R, Hor K, Mahler N, Yi T, Humphrey JD, Johnson J, Breuer CK, Hibino N. Oversized Biodegradable Arterial Grafts Promote Enhanced Neointimal Tissue Formation. Tissue Eng Part A 2018; 24:1251-1261. [PMID: 29431029 DOI: 10.1089/ten.tea.2017.0483] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Most tissue-engineered arterial grafts are complicated by aneurysmal dilation secondary to insufficient neotissue formation after scaffold degradation. The optimal graft would form an organized multilayered structure with a robust extracellular matrix that could withstand arterial pressure. The purpose of the current study was to determine how oversizing a biodegradable arterial scaffold affects long-term neotissue formation. Size-matched (1.0 mm, n = 11) and oversized (1.6 mm, n = 9) electrospun polycaprolactone/chitosan scaffolds were implanted as abdominal aortic interposition grafts in Lewis rats. The mean lumen diameter of the 1.6 mm grafts was initially greater compared with the native vessel, but matched the native aorta by 6 months. In contrast, the 1.0 mm grafts experienced stenosis at 6 and 9 months. Total neotissue area and calponin-positive neotissue area were significantly greater in the 1.6 mm grafts by 6 months and similar to the native aorta. Late-term biomechanical testing was dominated by remaining polymer, but graft oversizing did not adversely affect the biomechanics of the adjacent vessel. Oversizing tissue-engineered arterial grafts may represent a strategy to increase the formation of organized neotissue without thrombosis or adverse remodeling of the adjacent native vessel by harnessing a previously undescribed process of adaptive vascular remodeling.
Collapse
Affiliation(s)
- Cameron Best
- 1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.,2 Biomedical Sciences Graduate Program, The Ohio State University College of Medicine , Columbus, Ohio
| | - Takuma Fukunishi
- 3 Department of Surgery, Division of Cardiac Surgery, Johns Hopkins Hospital , Baltimore, Maryland
| | - Joseph Drews
- 1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.,4 Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio
| | - Ramak Khosravi
- 5 Department of Biomedical Engineering, Yale University , New Haven, Connecticut
| | - Kan Hor
- 6 Department of Cardiology, Nationwide Children's Hospital , Columbus, Ohio
| | - Nathan Mahler
- 1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio
| | - Tai Yi
- 1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio
| | - Jay D Humphrey
- 5 Department of Biomedical Engineering, Yale University , New Haven, Connecticut
| | | | - Christopher K Breuer
- 1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.,8 Department of Surgery, Nationwide Children's Hospital , Columbus, Ohio
| | - Narutoshi Hibino
- 3 Department of Surgery, Division of Cardiac Surgery, Johns Hopkins Hospital , Baltimore, Maryland
| |
Collapse
|
3
|
Birkholz M, Ehwald KE, Basmer T, Kulse P, Reich C, Drews J, Genschow D, Haak U, Marschmeyer S, Matthus E, Schulz K, Wolansky D, Winkler W, Guschauski T, Ehwald R. Sensing glucose concentrations at GHz frequencies with a fully embedded Biomicro-electromechanical system (BioMEMS). J Appl Phys 2013; 113:244904. [PMID: 25332510 PMCID: PMC3977869 DOI: 10.1063/1.4811351] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2013] [Accepted: 05/30/2013] [Indexed: 06/04/2023]
Abstract
The progressive scaling in semiconductor technology allows for advanced miniaturization of intelligent systems like implantable biosensors for low-molecular weight analytes. A most relevant application would be the monitoring of glucose in diabetic patients, since no commercial solution is available yet for the continuous and drift-free monitoring of blood sugar levels. We report on a biosensor chip that operates via the binding competition of glucose and dextran to concanavalin A. The sensor is prepared as a fully embedded micro-electromechanical system and operates at GHz frequencies. Glucose concentrations derive from the assay viscosity as determined by the deflection of a 50 nm TiN actuator beam excited by quasi-electrostatic attraction. The GHz detection scheme does not rely on the resonant oscillation of the actuator and safely operates in fluidic environments. This property favorably combines with additional characteristics-(i) measurement times of less than a second, (ii) usage of biocompatible TiN for bio-milieu exposed parts, and (iii) small volume of less than 1 mm3-to qualify the sensor chip as key component in a continuous glucose monitor for the interstitial tissue.
Collapse
Affiliation(s)
- M Birkholz
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - K-E Ehwald
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - T Basmer
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - P Kulse
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - C Reich
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - J Drews
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - D Genschow
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - U Haak
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - S Marschmeyer
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - E Matthus
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - K Schulz
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - D Wolansky
- IHP, Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - W Winkler
- Silicon Radar, Im Technologiepark 1, 15236 Frankfurt (Oder), Germany
| | - T Guschauski
- Humboldt Universität zu Berlin, Institut für Biologie, Invalidenstr. 42, 10115 Berlin, Germany
| | - R Ehwald
- Humboldt Universität zu Berlin, Institut für Biologie, Invalidenstr. 42, 10115 Berlin, Germany
| |
Collapse
|
4
|
Kusano Y, Drews J, Leipold F, Fateev A, Bardenshtein A, Krebs N. Influence of ultrasonic irradiation on ozone generation in a dielectric barrier discharge. ACTA ACUST UNITED AC 2012. [DOI: 10.1088/1742-6596/406/1/012006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
5
|
Hou Z, Cherian C, Drews J, Wu J, Matherly LH. Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. J Biol Chem 2009; 285:4732-40. [PMID: 20018840 DOI: 10.1074/jbc.m109.086033] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The reduced folate carrier (RFC) is the major transport system for folates in mammals. We previously demonstrated the existence of human RFC (hRFC) homo-oligomers and established the importance of these higher order structures to intracellular trafficking and carrier function. In this report, we examined the operational significance of hRFC oligomerization and the minimal functional unit for transport. In negative dominance experiments, multimeric transporters composed of different ratios of active (either wild type (WT) or cysteine-less (CLFL)) and inactive (either inherently inactive (Y281L and R373A) due to mutation, or resulting from inactivation of the Y126C mutant by (2-sulfonatoethyl) methanethiosulfonate (MTSES)) hRFC monomers were expressed in hRFC-null HeLa (R5) cells, and residual WT or CLFL activity was measured. In either case, residual transport activity with increasing levels of inactive mutant correlated linearly with the fraction of WT or CLFL hRFC in plasma membranes. When active covalent hRFC dimers, generated by fusing CLFL and Y126C monomers, were expressed in R5 cells and treated with MTSES, transport activity of the CLFL-CLFL dimer was unaffected, whereas Y126C-Y126C was potently (64%) inhibited; heterodimeric CLFL-Y126C and Y126C-CLFL were only partly (27 and 23%, respectively) inhibited by MTSES. In contrast to Y126C-Y126C, trans-stimulation of methotrexate uptake by intracellular folates for Y126C-CLFL and CLFL-Y126C was nominally affected by MTSES. Collectively, these results strongly support the notion that each hRFC monomer comprises a single translocation pathway for anionic folate substrates and functions independently of other monomers (i.e. despite an oligomeric structure, hRFC functions as a monomer).
Collapse
Affiliation(s)
- Zhanjun Hou
- Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA
| | | | | | | | | |
Collapse
|
6
|
Hucke T, Drews J, Traulsen T, Staub R, Fehrmann G, Stintz M, Gabsch S. Untersuchungen zu Struktur-Eigenschaftsbeziehungen an porösen Elektroden für implantierbare Li/MnO2-Batterien. CHEM-ING-TECH 2007. [DOI: 10.1002/cite.200700039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
7
|
Seemann R, Hägewald SJ, Sztankay V, Drews J, Bizhang M, Kage A. Levels of parotid and submandibular/sublingual salivary immunoglobulin A in response to experimental gingivitis in humans. Clin Oral Investig 2004; 8:233-7. [PMID: 15316859 DOI: 10.1007/s00784-004-0280-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2004] [Accepted: 07/07/2004] [Indexed: 11/24/2022]
Abstract
Salivary secretory IgA (s-IgA) is considered to act as an important first line of defense mechanism in the oral cavity. It has therefore been suggested that an increased antigenic load would induce an increase in salivary IgA production. This study investigated the pure glandular levels of salivary IgA in parotid and submandibular/sublingual (SM/SL) saliva during plaque accumulation leading to experimental gingivitis. Starting from regular oral hygiene, 14 healthy, nonsmoking men refrained from all oral hygiene measures for 12 days. On days -2, 0, 3, 6, and 12 a plaque index, a bleeding index, and unstimulated and stimulated saliva from the parotid and the SM/SL glands were measured. Salivary IgA was quantified using a sandwich ELISA. All subjects developed gingivitis as measured by a bleeding index. Compared to baseline the salivary flow rate was increased on day 12. Regarding the secretion rate of IgA there was a statistically significant increase in stimulated parotid saliva but not SM/SL saliva compared to baseline after 6 and 12 days without oral hygiene. No significant changes were observed for the concentration of IgA during the trial. Thus, in healthy subjects with regular oral hygiene the development of plaque induced gingivitis is associated with increased salivary gland output and increased total IgA output levels in stimulated parotid saliva but not in SM/SL saliva.
Collapse
Affiliation(s)
- R Seemann
- Department of Operative and Preventive Dentistry, Virchow Campus, Charité University Medical School of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
12 patients (10 males and 2 females, average age 53 years) were operated upon in our hospital between 1994 and 1999 for mycotic aneurysms. The aneurysms were located in 7 patients in the aorto-iliac segment, 5 patients were treated for peripheral or visceral aneurysms. Two of these patients suffered from multiple aneurysms. When peripheral arteries were affected, a pulsatile tumour was felt. Most of these tumours developed in a relatively short period of time and sometimes a perivascular inflammation occurred. This was not the case when central arteries were attacked. A septic process or an infection, for example salmonella-enteritis, often preceded shortly the development of a mycotic aneurysm. In the case of an aneurysm of the aorto-iliac section we consider an in situ reconstruction with alloplastic material in combination with a perivascular debridement, lavage and omentum majus plastic as the treatment of choice. In peripheral arteries reconstruction should be performed with autologous vessels. Depending on the local findings, a perivascular debridement should also be performed in these cases. The reconstruction always should be combined with a calculated antibiotic therapy. Two of our patients died perioperatively. During follow up, 8 patients showed patent reconstructions and no signs of infection. The urgency of surgery depends on the level of inflammation and the existence of any secondary complications.
Collapse
Affiliation(s)
- F Klein
- Klinik für Allgemein, Gefäss und Thoraxchirurgie, Klinikum Neubrandenburg, Germany
| | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- J Drews
- International Biomedicine, Management Partners AG, House of Commerce, Aeschenplatz 7PO Box 136, CH-4010, Basel, Switzerland
| |
Collapse
|
10
|
Abstract
Those following the financial markets and the valuation of biotechnology companies recently might find themselves perplexed. Towards the end of 1999, during which the availability of capital for biotech initial public offerings and for private investment rounds seemingly withered, the markets suddenly turned around and gave the biotechnology industry its biggest bonanza ever.
Collapse
Affiliation(s)
- J Drews
- International Biomedicine Management Partners, Basel Switzerland and Managing Partner, Bear Stearns Health Innoventures, New York, NY, USA
| |
Collapse
|
11
|
Abstract
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.
Collapse
Affiliation(s)
- J Drews
- International Biomedicine Management Partners, Basel, Switzerland and Orbimed Advisors LLC, New York, NY 10017-2023, USA
| |
Collapse
|
12
|
Affiliation(s)
- J Drews
- International Biomedicine Management Partners in Basel, Switzerland.
| |
Collapse
|
13
|
Affiliation(s)
- J Drews
- Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
14
|
Abstract
The usage of a 6 V lithium manganese dioxide battery results in a significant reduction of capacitor loading time within implantable defibrillators/cardioverters. In order to provide ERI indication a new cathode formulation has been developed. The battery shows no voltage delays, a low self-discharge and fulfilled all requirements to an energy source for an implantable device.
Collapse
Affiliation(s)
- J Drews
- LITRONIK, Batterietechnologie GmbH & Co., Pirna
| | | | | | | |
Collapse
|
15
|
Affiliation(s)
- J Drews
- Hoffmann-La Roche, Basel, Switzerland.
| | | |
Collapse
|
16
|
Affiliation(s)
- J Drews
- Hoffmann-La Roche, Nutley, New Jersey 07110-1199, USA
| |
Collapse
|
17
|
Drews J. Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. Arzneimittelforschung 1995; 45:934-9. [PMID: 7575764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Drug research developed around a purpose: the cure of diseases. This intent to cure, however, offered no clue to the understanding of diseases and to their treatment. Instead such guidance had to come from scientific disciplines which laid the foundations for drug research and offered specific opportunities for the solution of therapeutic problems. In the sequence of their appearance, these scientific disciplines were: chemistry, pharmacology/physiology, microbiology, biochemistry and molecular biology. It can be shown that new therapeutic classes of drugs like muscle relaxants, diuretics, L-dopa, antibiotics, recombinant proteins, monoclonal antibodies and others were generated on the basis of scientific opportunities rather than therapeutic need. All of these drugs were created within the confines of a chemical paradigm of medicine and drug therapy. We are now witnessing the entry of a new informational paradigm into medicine which is most prominently represented by genomic sciences. This paradigm will bring two important changes to the therapy of diseases. First, molecular biology has matured to such a degree that it can now study complex genomes and their functionality in complex organisms such as humans. Therefore, results from these studies no longer have to be translated into the context of medicine: they are already within this context. Secondly, drug therapy which used to be largely symptomatic, will now aim at targets which are closer to the causes of diseases than previously. Therapeutic progress, which used to be indirect, conjectural and coincidental, is about to become more directed, definitive and intentional. At least from the limited and utilitarian perspective of medicine, drug discovery will be more often based on intent rather than coincidence. But industry and, for that matter, society as a whole should not forget that this situation has come about through the evolution of science which was not, and can never be, predictable.
Collapse
|
18
|
Drews J. Medical need or scientific opportunity: What drives drug research? Pharmacol Res 1995. [DOI: 10.1016/1043-6618(95)86342-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Drews J. Novel immunological pathways to the treatment of infections. Infection 1994; 22:157-9. [PMID: 7927809 DOI: 10.1007/bf01716694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
20
|
Affiliation(s)
- J Drews
- Hoffmann-La Roche, Nutley, New Jersey 07110-1199
| |
Collapse
|
21
|
Drews J. Medicine and genetic engineering: just another method or a new paradigm? Arzneimittelforschung 1991; 41:94-100. [PMID: 2049117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Scientific and technical developments have influenced medicine in a more profound way than any other cultural forces. In our days, molecular biology appears to be the major scientific factor which forms medicine. To those who practise medicine in the clinical environment, this statement may come as a surprise; however, if one looks at therapeutic and diagnostic research, the magnitude of change becomes evident. Most of these changes can still be interpreted in the context of known categories. In the analysis of the human genome, as well as in somatic gene therapy, however, a new principle emerges which will change our understanding of disease in a profound way. The scientific interpretation of disease as well as of diagnosis and therapy was first based on a morphological paradigm, which can be traced back to R. Virchow as well as to his contemporaries and successors. This powerful paradigm was later complemented by a chemical or biochemical paradigm which turned out to be extremely useful: modern diagnostics based on clinical chemistry as well as drug therapy are direct consequences of this influence. The new understanding of disease, diagnosis and treatment, which molecular biology is affording, is centered around the concept of genetic information. Diseases can be interpreted as informational deficits, as manifestations of faulty, inadequate or surplus information. While disease was previously interpreted on the basis of alterations in form and function it can now be seen as a derangement of the flow of information within cells, between cells, and between organs. The consequences for strategies of diagnosis and treatment will be profound.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J Drews
- F. Hoffman-La Roche Ltd, Forschungsleitung, Basle, Switzerland
| |
Collapse
|
22
|
Drews J. [Medicine and genetic technic. Do we need a new ethic?]. Swiss Dent 1990; 11:7-10. [PMID: 2114676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
23
|
Abstract
The progress of pharmaceutical research depends on three factors: on the evolution of medical needs, on societal attitudes, and on scientific and technical feasibility. Among the factors which are 'internal' to science, molecular biology seems to be the most important driving force, at least for the foreseeable future. The influence of molecular biology on pharmaceutical research is occurring in several distinct phases. The first phase was characterized by the use of gene technology as a production instrument for known proteins. In the second phase, gene technology is instrumental in the identification of novel proteins and in the elucidation of their gene structure and physiological function. A great number of proteins which have therapeutic potential will eventually emerge from this phase, with the more important ones like the hematopoietic factors yet to come. During the third phase, gene technology will provide proteins that can serve as pharmacological tools: receptors, ligands, enzymes, cytokines and other proteins provided by gene technology will enable us to open up new fields of pharmacology from which novel drugs, often low molecular weight chemical entities, will emerge. Finally the fourth phase will be characterized by a knowledge of gene structure and regulation extensive enough to develop a pharmacology of gene regulation and to establish somatic gene therapy. New drugs that can be expected to emerge from the interaction of molecular biology and pharmaceutical research within the next ten to twelve years are discussed. It is expected that pharmaceutical research will in the end be transformed into a discipline in which molecular biology and structural chemistry play dominating roles while synthetic chemistry will be reduced to the role of an important tool.
Collapse
Affiliation(s)
- J Drews
- La Roche Ltd., Basel, Switzerland
| |
Collapse
|
24
|
Drews J. The stimulation of unspecific resistance--a doctor's dilemma revisited. Infection 1989; 17:201-2. [PMID: 2788619 DOI: 10.1007/bf01639519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- J Drews
- F. Hoffmann-La Roche AG, Basel, Switzerland
| |
Collapse
|
25
|
Abstract
One of the causes of anaemia in rheumatoid arthritis is thought to be defective iron absorption. In this study the 59Fe absorption in patients with active rheumatoid arthritis is measured and correlated with the results for bone marrow iron stores (and in some cases with the iron stores in the terminal duodenum), which were assessed simultaneously with semiquantitative methods, and with the serum ferritin concentration. In 11 patients with rheumatoid arthritis and increased bone marrow iron stores, iron absorption was decreased. In five patients it was normal and in three further patients, whose bone marrow iron stores were depleted, iron absorption was maximally increased. According to the results both intestinal malabsorption and defective iron absorption can be excluded as causes.
Collapse
Affiliation(s)
- H P Benn
- Second Department of Internal Medicine, University of Kiel, FRG
| | | | | | | | | |
Collapse
|
26
|
Abstract
Therapeutic agents capable of stimulating immune responses could be of great value in the prophylaxis and treatment of infectious diseases. Three classes of compounds, each representing a separate approach to the goal of immune stimulation, are discussed with respect to recent experimental and clinical findings. The action of microbial structures and their derivatives can be understood on the basis of "acquired cellular immunity", a phenomenon first described in connection with infections by mycobacteria and other intracellular organisms. In contrast, there is hardly a common denominator for synthetic compounds which are currently used as immune-stimulatory agents. Substances which influence purine metabolism in lymphocytes on the one hand and histamine H2 blockers such as cimetidine on the other hand seem to represent the most promising developments in this field to date. Products of immune cells such as transfer factor and lymphokines form the third and possibly most important group of immune-stimulating agents. Current experimental and clinical trends in this field are briefly described. It is suggested that the delineation of the mechanism of action of lymphokines will open the door to the identification or synthesis of artificial agonists and antagonists as has been the case in the pharmacology of the endocrine and nervous systems.
Collapse
|
27
|
Gassmann W, Haferlach T, Schmitz N, Kayser W, Euler HH, Drews J, Löffler H. [Analysis of prognostic factors in plasmacytoma]. Klin Wochenschr 1984; 62:896-905. [PMID: 6503212 DOI: 10.1007/bf01727438] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
For analysis of prognostic factors the clinical course of 109 patients with multiple myeloma was evaluated. Survival curves of immunoglobulin (Ig)G- and IgA-myelomas were identical (Fig. 1) with median survival times of 52 and 42 months, respectively, whereas patients with IgD- and Bence-Jones-myeloma had short survival times (median 3 months). Most important risk factors were anemia, renal insufficiency, and hypercalcemia (Figs. 7 and 8). Median survival time dropped from 52 months (Hb above 100 g/l) to 22 (Hb 85-100 g/l) and 1 month (Hb below 85 g/l). Patients with serum creatinine values below 2 mg/dl lived significantly longer than those with values above. Median survival times were 52 and 1 month, respectively. All seven hypercalcemic patients had a renal insufficiency and were in a very poor condition; their median survival time was 1 month. Analysis of the widely used staging system of Durie and Salmon gave disappointing results. Survival curves of the three A-stages ran close together with median survival times of 58, 51, and 36 months. Only the A-B classification according to renal function (A: creatinine under 2 mg/dl; B: creatinine above 2 mg/dl) proved prognostically relevant.
Collapse
|
28
|
Abstract
Three classes of immunostimulating drugs are described, each representing a different approach to the problem of pharmacological immunostimulation. The rationale for the use of microbes or microbial agents as immunostimulators rests on the fact that some micro-organisms, especially those that replicate intracellularly, carry a special potential to activate macrophages. Clinically, the use of these agents in patients with tumors and infections has been disappointing; however, there have been positive exceptions like the responsiveness of melanomas and bladder carcinomas to the injection of BCG. Many of the inconclusive results may be due to insecurities in the dosage of microbial preparations and to a general lack in standardization. Some structures with high efficacy and low toxicity which have recently evolved from this field deserve further investigation. A number of structurally unrelated synthetic compounds was found to influence immune parameters. Levamisole can today be classified as an immunostimulating drug with limited utility in recurring infections and in chronic polyarthritis. Several immunostimulating drugs which have attracted interest contain a purine as the effective component. This is not surprising in view of the fact that many genetically determined immunodeficiencies can be traced to defects of enzymes which play a crucial role in purine biosynthesis. Finally, the potential role of lymphokines as stimulators of the immunosystem is briefly described. Some of these glycoproteins have recently become available for clinical trials. Others will be made available through genetic engineering. The therapeutic utility of these compounds is not yet clear; they will, however, be of great value as probes for the study of immune functions and for the development of immunopharmacology.
Collapse
|
29
|
Abstract
Therapeutic agents capable of stimulating immune responses could be of great value in the prophylaxis and treatment of infectious diseases. Three classes of compounds, each representing a separate approach to the goal of immune stimulation, are discussed with respect to recent experimental and clinical findings. The action of microbial structures and their derivatives can be understood on the basis of "acquired cellular immunity", a phenomenon first described in connection with infections by mycobacteria and other intracellular organisms. In contrast, there is hardly a common denominator for synthetic compounds which are currently used as immune-stimulatory agents. Substances which influence purine metabolism in lymphocytes on the one hand and histamine H2 blockers such as cimetidine on the other hand seem to represent the most promising developments in this field to date. Products of immune cells such as transfer factor and lymphokines form the third and possibly most important group of immune-stimulating agents. Current experimental and clinical trends in this field are briefly described. It is suggested that the delineation of the mechanism of action of lymphokines will open the door to the identification or synthesis of artificial agonists and antagonists as has been the case in the pharmacology of the endocrine and nervous systems.
Collapse
|
30
|
Drews J. A chance for revival? Eur J Clin Pharmacol 1984. [DOI: 10.1007/bf00548755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
|
32
|
Drews J. [Plunge into the unconscious. Construction of dreams and day dreams in Arno Schmidt's novel, "Kaff auch mare Crisium" (1960)]. Psyche (Stuttg) 1981; 35:1103-21. [PMID: 7031782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
33
|
Abstract
Naftifine exhibits an interesting in vitro spectrum of activity against dermatophytes (38 strains; minimal inhibitory concentration [MIC] range 0.1 to 0.2 microgram/ml), aspergilli (6 strains; MIC range, 0.8 to 12.5 microgram/ml), Sporothrix schenckii (2 strains; MICs, 0.8 and 1.5 microgram/ml), and yeasts of the genus Candida (77 strains; MIC range, 1.5 to greater than 100 microgram/ml). Its degree of efficacy is unaffected by the organism density in the test medium, and it is primarily fungicidal against dermatophytes as well as yeasts. Its in vitro efficacy is pH dependent and rises with increasing pH values.
Collapse
|
34
|
Herrlinger JD, Kriegel W, Drews J, Hölscher F, Schmidt R. [Clinical trial in couples of effectiveness and side-effects of gold and D-penicillamine in long term treatment of rheumatoid arthritis (author's transl)]. Klin Wochenschr 1980; 58:839-45. [PMID: 7005521 DOI: 10.1007/bf01491105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A prospective clinical trial in couples was done to compare effectiveness and toxicity of gold and D-penicillamine (D-Pen.) in treatment of rheumatoid arthritis (r.A.). Respecting defined criteria 70 patients were put to couples according to a random list and were treated with gold or D-Pen. alternatively. Physical and laboratory indices of inflammatory activity were checked every 3 months, X-rays every 12 months. Dropouts (side effects, missing compliance, uneffectiveness) were replaced by the nextcoming fitting patient. Thirty-two of 147 totally recruited patients stopped treatment because of side effects, three because of unsatisfying efficiency. Forty-two patients shuned the necessary controls. The clinical course was better in 16 couples with gold, only in sex couples with D-Pen. Thirteen pairs showed no difference in this respect (p = 0.05). Looking to the laboratory parameters separately D-Pen. tends to be superior (p < 0.05), radiografic deterioration seems to be more seldom with gold (< 0.05). Side effects occur with both drugs in comparable frequency (15/44 with D-Pen., 17/52 with gold), but the complications with D-Pen. are more serious. Altogether this trial shows gold superior to D-Pen. in the long-term treatment of r.A.
Collapse
|
35
|
Abstract
The new antilymphocytic agent Cyclosporin A was found to inhibit the production and/or secretion of migration inhibitory factor (MIF) in human lymphocytes stimulated by Concanavalin A. Preincubation for one hour with the compound, followed by 8 hr restoration period of the cells in absence of the drug, resulted in moderate decrease in MIF synthesis and/or release. Cell viability was not affected. The agent was shown not to interfere with MIF action on the macrophage. We conclude that the molecular mechanism of action of Cyclosporin A is based, at least partially, on a blockade of synthesis and/or secretion of lymphokines from immunocompetent cells.
Collapse
|
36
|
Ilmer S, Drews J. Differential analysis of selected prompts and neurological variables in motor assessment of moderately mentally retarded children. Am J Ment Defic 1980; 84:508-17. [PMID: 7361828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The purpose of this study was to elevate the specificity of gross-motor assessment strategies presently used with moderately mentally retarded children by measuring voluntary motor performance as a function of level of reflex development, level of orthopedic functioning, and type of prompts used in test instructions. After clinically assessing subjects' levels of reflex and orthopedic functioning, we randomly assigned subjects to multisensory-, physical-, modeling-, and verbal-prompt treatment groups. Multisensory prompts and differential use of selected prompts were effective with younger and older children, respectively. A significant interrelationship was found between subjects' levels of reflex development and voluntary motor performance.
Collapse
|
37
|
|
38
|
Mayer P, Drews J. The effect of a protein-bound polysaccharide from Coriolus versicolor on immunological parameters and experimental infections in mice. Infection 1980; 8:13-21. [PMID: 6966256 DOI: 10.1007/bf01677393] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The influence of PSK, a protein bound polysaccharide from Coriolus versicolor on various immunological parameters was studied, PSK was found to enhance B cell activity as measured by the spleen plaque-forming cell assay in mice, and to stimulate mouse macrophages as determined by an enhancement of carbon clearance and an increase in the phagocytosis of opsonized sheep red blood cells by peritoneal mouse macrophages in vitro. The activation of mouse macrophages by PSK appeared to correlate with the therapeutic effects of the compound. In mice made granulocytopenic with cyclophosphamide and subsequently infected with a variety of garm-negative pathogens or with Candida albicans, PSK prolonged the average survival time of the animals. The compound also led to a drastic increase in the number of animals surviving such experimental infections as compared to untreated controls. Possible mechanisms responsible for these protective effects by PSK are discussed.
Collapse
|
39
|
Drews J, Nolan RD. 8. Zukunftsaussichten bei der Behandlung von Infektionen in der Chirurgie. Langenbecks Arch Surg 1979. [DOI: 10.1007/bf01729466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Drews J. [Resistance plasmids in bacterias. Molecular characteristics, epidemiology and clinical significance]. Med Klin 1979; 74:935-44. [PMID: 460032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
41
|
|
42
|
Grasmuk H, Nolan RD, Drews J. The isolation and characterization of elongation factor eEF-Ts from Krebs-II mouse-ascites-tumor cells and its role in the elongation process. Eur J Biochem 1978; 92:479-90. [PMID: 738276 DOI: 10.1111/j.1432-1033.1978.tb12770.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A factor having activity similar to that described in other systems for the eukaryotic elongation factor eEF-Ts was isolated from the heavy, aggregate form of eEF-TH (formally named EF-1H). This protein has a molecular weight of 52000 under native conditions and of 25500 under denaturing conditions. It has been shown to stimulate eEF-Tu-dependent aminoacyl-tRNA binding to ribosomes and therefore eEF-Tu/eEF-G-dependent polyphenylalanine synthesis by ribosomes and was found to stimulate GDP-GTP exchange in eEF-Tu . GDP complexes. In the course of this work, it was also demonstrated that the removal of deacylated tRNA from the ribosome is a GTP-dependent process. This report, therefore, adds further support to the concept that a third elongation factor, eEF-Ts, may be common to all systems in the eukaryotic domain.
Collapse
|
43
|
Abstract
A lipid fraction from Escherichia coli was extracted with apolar solvents and was found to protect mice from a number of experimental bacterial infections. The benzoquinone, ubiquinone-8, was isolated from this extract by high pressure liquid chromatography and identified as such by nuclear magnetic resonance and mass spectrometry. At a dose of 25 mg/kg this substance was found to provide complete protection against otherwise lethal infections with gram-negative and gram-positive bacteria in mice. Treatment was most effective when given intravenously 24 h before infection. In comparative studies, ubiquinone-8 had a clearly higher activity than ubiquinones-4, Q6, and Q10. A highly significant increase in the clearance rate of bacteria from the blood by the spleen and the liver of treated animals, correlated well with the protective effect of ubiquinone-8. The compound stimulated the ability of mouse macrophages to incorporate sheep erythrocytes and significantly increased the number of antibody-producing cells in spleens of mice.
Collapse
|
44
|
Grasmuk H, Nolan RD, Drews J. Interchangeability of elongation factor-Tu and elongation factor-1 in aminoacyl-tRNA binding to 70 S and 80 S ribosomes. FEBS Lett 1977; 82:237-42. [PMID: 334567 DOI: 10.1016/0014-5793(77)80592-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
45
|
Grasmuk H, Nolan RD, Drews J. Further evidence that elongation factor 1 remains bound to ribosomes during peptide chain elongation. Eur J Biochem 1977; 79:93-102. [PMID: 242941 DOI: 10.1111/j.1432-1033.1977.tb11787.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
This paper describes three types of experiments which indicate that the binding sites for elongation factor 1 (EF-1) and elongation factor 2 (EF-2) on ascites cell ribosomes are not identical and perhaps not even overlapping. The experimental evidence presented includes direct competitive binding of labeled elongation factors to ribosomes as well as the influence of pokeweed antiviral protein and Escherichia coli anti L7/L12 proteins on the binding and function of the two factors. It is further shown that EF-1beta from Artemia salina does not function in displacing EF-1 from mouse ascites tumor cell ribosomes. These results also support our recently proposed model that EF-1 remains bound to the ribosome during the peptide chain elongation cycle.
Collapse
|
46
|
Abstract
An entirely new model for the mechanism of elongation factor 1 (EF-1) function is presented. Experiments in which mixtures of [3H]EF-1, ribosomes from Drebs II ascites cells and various additional co-factors were analyzed by chromatography on Sepharose 6B, show that EF-1 binds to the ribosome early in the translation process and remains bound on the ribosome during translation. Optimal EF-1 binding occurs on polynucleotide-programmed ribosomes carrying a tRNA in their P-site. On the other hand it was clearly shown that EF-2 attached at each translocation event and was then released before a new Phe-tRNA could be bound.
Collapse
|
47
|
Grasmuk H, Nolan RD, Drews J. Functional identity of the monomeric and multiple forms of elongation-factor 1 from Krebs-II mouse ascites-tumor cells. Eur J Biochem 1976; 67:421-31. [PMID: 964253 DOI: 10.1111/j.1432-1033.1976.tb10707.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Highly purified 3H-labelled elongation factor 1 (EF-1) from Krebs II mouse ascites tumour cells was separated into biologically active monomeric and aggregate forms of the enzyme by either gradient centrifugation or gel filtration. When corrected for their content of inactive enzyme both forms of the factor were found to be equally active whether tested in the binding or synthesis reaction. The only form of the enzyme found bound to ribosomes was the monomer; it was therefore concluded that the aggregate form of the enzyme must first dissociate before it reacts with the ribosome. The stoichiometry of the aminoacyl-tRNA binding reaction to ribosomes in the presence of guanosine nucleotides was also studied. It was found that one molecule of aminoacyl-tRNA and of Guo-5'-P2-CH2-P is bound per molecule of EF-1 bound to the ribosome. Following interaction with a release from, the ribosomes, EF-1 was found to be predominantly monomeric.
Collapse
|
48
|
Abstract
Acquired resistance can be defined as a qualitative alteration of the genetic material of a cell which is phenotypically correlated with a measurable decrease of the cell's sensitivity against one or several chemotherapeutic agents. There are two basic genetic mechanisms which can lead to the emergence of resistance: mutation and the acquisition of additional genetic material from another cell. Both forms of resistance play an important role in clinical situations: the emergence of resistance by mutation occurs in tumor cells and can also lead to therapeutic problems in antimicrobial chemotherapy. In bacteria, however, acquisition of resistance plasmids represents the dominating mechanism which is responsible for most therapeutic problems in the clinical environment. The different genetic mechanisms involved in the emergence of resistance are paralleled -- at least in bacteria -- by two principally different groups of biochemical mechanisms implementing resistance. Mutations lead to alterations of single cell constituents such as the cell membrane or cellular receptors necessary for the binding of the antimicrobial agent. This form of resistance is biochemically characterized by the inaccessibility of the cell interior for a particular compound or by the modification of an intracellular binding site which loses its affinity for the chemotherapeutic agent. Resistance plasmids on the other hand code for enzymes which inactivate the antibiotic (beta-lactamases, aminoglycosideinactivating enzymes, chloramphenicol-acetyltransferase); In some cases, they direct the synthesis of proteins which affect cell permeability (tetracycline) or isoenzymes which have a lower affinity for the inhibitor (trimethoprim). Resistance against antibiotics can be inducible; In these cases the regulatory mechanisms involved are stable genetical traits as resistance itself; Using chloramphenicol, beta-lactam-antibiotics and aminoglycosides as examples, it is demonstrated that resistance data gathered early in the development of a new drug are of little value in estimating the clinical potential of a new compound. Information on the rate at which resistance develops, on the pattern according to which it emerges ("single step" or "multi step") and on cross-resistance patterns is important in the characterization of a new drug but is often invalidated by later findings obtained in the clinical environment; The problem appears somewhat simpler if a new drug is a member of an already known class of compounds, e.g. a beta-lactam or an aminoglycoside. In such cases our knowledge of frequent enzymatic inactivation mechanisms provides a basis not only for the evaluation of an existing drug, but also for the synthesis of new derivatives.
Collapse
|
49
|
Nolan RD, Grasmuk H, Drews J. The binding of tritiated elongation-factors 1 and 2 to ribosomes from Krebs II mouse ascites-tumore cells. The influence of various antibiotics and toxins. Eur J Biochem 1976; 64:69-75. [PMID: 1278160 DOI: 10.1111/j.1432-1033.1976.tb10275.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The effect of a number of different antibiotics and toxins on the capacity of Krebs II mouse ascites ribosomes to bind 3H-labelled elongation factors (EF-1 and EF-2) has been examined. It was found that abrin and ricin inhibit the binding of EF-2, while diphtheria toxin, sparsomycin, streptovitacin A, and cycloheximide had essentially no effect on its binding. Of the other compounds examined, sparsomycin was unique in its capacity, under some circumstances, to significantly affect the binding of aminoacyl-tRNA and EF-1 to ribosomes. Fusidic acid appears to nonspecifically enhance the binding of both EF-1 and EF-2.
Collapse
|
50
|
Hodgin LA, Drews J. Effect of active and passive immunizations with lipid A and salmonella minnesota Re 595 on gram-negative infections in mice. Infection 1976; 4:5-10. [PMID: 789248 DOI: 10.1007/bf01638340] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The capacity of lipid A, a structure common to the lipopolysaccharide cores of all gram-negative bacteria, to serve as an active immunizing agent in mice and to protect these animals against gram-negative infections was investigated. Active immunization experiments were also performed with the Re mutant of Salmonella minnesota 595 which carries a lipopolysaccharide composed of lipid A and three residues of ketodeoxyoctonic acid. Single injections of lipid A complexed to acid-hydrolyzed bacteria as carriers failed to induce specific protection against subsequent challenge infections with E. coli O4 and S. breslau. Repeated injections of lipid A resulted in good protection against intraperitoneal challenge with S. breslau and partial protection against intravenous challenge with the same organism but did not alter the sensitivity of mice to challenge infections with E. coli or Pasteurella multocida. Whole antisera or serum fractions from rabbits in which high titers against lipid A had been attained by repeated intravenous injections of the antigen did not protect mice against challenge infections with E. coli O4. In contrast a single injection of the Re mutant of S. minnesota antigen in combination with incomplete Freund's adjuvant provided substantial protection against an otherwise lethal intraperitoneal infection with S. breslau over a period of at least 45 days. Repeated application of the Re antigen resulted in partial protection against experimental infections with E. coli O4, S. breslau and Pasteurella multocida. Injections of S. minnesota Re 595 antiserum provided better protection against an E. coli O4 infection than lipid A sera or antibodies of the IgG or IgM type directed against this antigen.
Collapse
|